Washington's decision to join Japan in supporting the battered yen has prompted questions over what motivated the rare ...
2h
Political voices can't fight against market realities to have a weaker U.S. dollar at the moment: PM
Ten Cap’s Jun Bei Liu says that while a weaker U.S. dollar would support global investor sentiment, potential rate hikes and ...
Louise Loo, Head of Asia Economics at Oxford Economics says Beijing is preparing to deploy a significant arsenal of unspent ...
Kinger Lau of Goldman Sachs said Hong Kong-listed internet platforms are becoming attractive as investors rotate out of ...
Feroze Azeez, CEO of Anand Rathi Wealth breaks down the mechanics behind the massive shift in Foreign Institutional Investor ...
Cyrus Mewawalla, Head of Strategic Intelligence at Globaldata PLC explains that while semiconductor companies may not face an ...
Bob McNally, President of Rapidan Energy Group, says oil markets struggle to price rare, low-probability events such as a ...
Amena Bakr, Head of Middle East and OPEC+ Insights at Kpler says she expects oil prices to continue spiking given the lack of ...
9h
Beijing is gradually normalizing its control over the South China Sea with small, incremental acts
Lynn Kuok, Lee Kuan Yew Chair in Southeast Asian Studies at Brookings Institutions, discusses how China's strategy in the ...
TMX Global Markets and Post Trade's Luc Fortin says TMX Australia Exchange will open up opportunities for SMEs to get ...
AstraZeneca shares dropped as much as 7% after a report that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if completed, could value the companies ...
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results